Have a question for our experts?

Send us an email to

EDITORIAL ADVISORY BOARD (EAB) MEMBERS

MARGARET ANDERSON
Managing Director,
Deloitte
 

CHARLENE BANARD
Head of Quality for Technical Operations, Shire
 

RICHARD BARON
Board of Directors,
Aspire Bariatrics, Inc.
 

JEFFREY BERKOWITZ
Former EVP,
UnitedHealth Group

LIZ BYWATER, Ph.D.
President, Bywater
Consulting Group

.

RON COHEN, M.D.
President and CEO,
Acorda Therapeutics, Inc.

.

LAURIE COOKE
CEO, Healthcare
Businesswomen’s
Association (HBA)

RICH DALY
Chairman and CEO,
Neuralstem, Inc

RAUL DIAZ
Plant Manager,
MSD Pharmaceutical Operations, Merck, Mexico

 

TOM DILENGE
President, Advocacy,
Law & Public Policy Division
Biotechnology Innovation Organization

TIM GARNETT
CMO, Eli Lilly

RON GUIDO
President, Lifecare Services, LLC

ANU HANS
VP & CPO Enterprise
Supply Chain, J&J

FRED HASSAN
Managing Director,
Warburg Pincus

PAUL HASTINGS
Chairman & CEO, OncoMed Pharmaceuticals

JOHN HUBBARD, PH.D.
Independent Director and
Board Member, Agile Therapeutics

MAIK JORNITZ
CEO, G-CON Manufacturing Inc.

 

MITCH KATZ, PH.D.
Head of Clinical Research
and Drug Safety Operations, Purdue Pharma L.P.

MARY ROSE KELLER
Vice President, Clinical Operations Heron Therapeutics

RACHEL KING
CEO, GlycoMimetics

 

SURESH KUMAR
Former EVP External Affairs,
Sanofi

 

JOHN LAMATTINA, PH.D.
Senior Partner,
PureTech Health

 

CRAIG LIPSET
Head of Clinical Innovation,
Worldwide Research &
Development Pfizer

Sandy Macrae, M.B., Ch.B.
Ph.D. President and CEO, Sangamo Therapeutics

KENNETH MOCH
President and CEO,
Cognition Therapeutics

BERNARD MUNOS
Founder, InnoThink Center for
Research in Biomedical Innovation

CAROL NACY, PH.D.
CEO, Sequella, Inc.

FRANCOIS NADER, M.D.
Chairman of the Board, 
Acceleron Pharma

SESHA NEERVANNAN, PH.D.
VP Pharmaceutical Development Allergan

 

MARK PETRICH, PH.D.,
PE Director, Component Engineering Global Sterile &
Validation Center of Excellence, Merck

SANDRA POOLE
Former EVP, Technical Operations,
ImmunoGen, Inc.

DENNIS J. PURCELL
Founder and Senior Advisor,
Aisling Capital LLC

DAVID PYOTT
Chairman of the Board, Bioniz Therapeutics

CHANDRA RAMANATHAN,
PH.D. M.B.A. VP and Head, East Coast Innovation Center, Bayer

JOHN REYNDERS, PH.D.
VP, Data Sciences, Genomics, and Bioinformatics, Alexion

STEPHEN RAPUNDALO, PH.D.
President and CEO,
Mich Bio

JAMES ROBINSON
Independent Manufacturing
Consultant, Merck

TOMASZ SABLINSKI, M.D., PH.D.Cofounder & CEO,
Transparency Life Sciences

ANDREW SKIBO
EVP Operations, MedImmune
RVP, AstraZeneca

 

JASON URBAN, PH.D.
Sr. Director Business
Operational Excellence,
Celgene Corporation

LESLIE WILLIAMS
Founder, President,
and CEO, ImmusanT

 

IN THIS MONTH'S ISSUE

  • What Does The Trump Pivot Mean For Healthcare?

    Frustrated with congressional Republican inaction on major pieces of his agenda, President Trump cut deals with Democrats on a short-term increase in the debt ceiling and funding the government. Then to the surprise and consternation of his base, Trump agreed to work on a deal to extend DACA, a Democratic priority. But what does Trump’s new interest in working with Democrats mean for healthcare policy-making? That is not yet clear.

  • A Name Change — And More — For A Biotech

    When Maria Fardis, Ph.D., MBA, joined Lion Biotechnologies as CEO, she knew “The word ‘Lion’ didn’t really define us as a company or the advancements we had made with our TIL technology.” So, nine months into her tenure, Fardis and her team began the process of changing the company name to Iovance.

  • Can AI Deliver Faster, Better Drug Development?

    As the cost of developing new medicines continues to rise, more pharmaceutical companies are looking at how artificial intelligence (AI) can help in drug development. But there are some hurdles to overcome before its full potential is reached.

  • How Moving Up Through The Ranks Can Shape A Biotech CEO

    All CEOs of small, publicly traded biotechs are required to wear many hats in the office every day. That’s why having a leader with a diverse background and experience in a variety of functional areas is an asset. Here we look at some of the various areas of expertise that can help create a more diverse C-suite executive.

  • Why South Korea Is The Hottest Growth Spot For Clinical Trials

    “The Korean pharmaceutical industry has been accelerating investments in open innovation and focusing on R&D for entry into overseas markets,” says Deborah Chee, president, Korean National Enterprise for Clinical Trials.

More From Current Issue

@LIFESCILEADER1

 EVENTS

How to Write SOPs That are GCP Compliant and Implementable October 17, 2017
1pm-2:30pm EDT, Online Training
Price:  $299 - Includes Bonus Handouts!
Outsourced Pharma October 17 - 18, 2017
San Francisco , CA
Outsourced Pharma October 17 - 18, 2017
San Francisco , CA
BIO Investor Forum October 17 - 18, 2017
San Francisco, CA